New oxovanadium(IV) complexes overcame drug resistance and increased in vitro cytotoxicity by an apoptotic pathway in breast cancer cells

Basit Öğe Kaydı
dc.authoridSert, Esra/0000-0002-7383-8619
dc.authoridKaya, Busra/0000-0003-2706-172X
dc.contributor.authorKalindemirtas, Ferdane Danisman
dc.contributor.authorKaya, Buesra
dc.contributor.authorSert, Esra
dc.contributor.authorSahin, Onur
dc.contributor.authorKuruca, Serap Erdem
dc.contributor.authorUlkuseven, Bahri
dc.date.accessioned2025-03-23T19:41:53Z
dc.date.available2025-03-23T19:41:53Z
dc.date.issued2022
dc.departmentSinop Üniversitesi
dc.description.abstractIn order to examine the anticancer potential of oxovanadium(IV) complexes with thiosemicarbazone, two new complexes were prepared starting from 2-thenoyltrifluoroacetone-S-methylthiosemicarbazone. The complexes with tetradentate thiosemicarbazone ligand were characterized by elemental analysis, IR, ESI MS, and single crystal X-ray diffraction analysis. Cytotoxicity on breast cancer cells, MDA-MB-231 and MCF-7, was determined by MTT assay. Cisplatin was positive control and the results were compared with those of the normal cells, HUVEC and 3T3. The complexes exhibited greater activity on cancer cells than cisplatin, but they were cytotoxic at several times higher concentrations in the healthy cells. In our study, the presence of thiophene and fluoro groups in the oxovanadium(IV) complexes with thiosemicarbazone increased greatly the cytotoxic activity of the complexes on breast cancer cells. Moreover, the complexes induced apoptosis-mediated cell death and also reduced the expression of MDR-1 or P-glycoprotein and ABCG2. As a result, the findings indicated that the complexes have selective cytotoxicity on breast cancer cells and can overcome multidrug resistance. These properties of the complexes make it possible to be a potential anticancer drug candidate for breast cancer treatment.
dc.description.sponsorshipScientific Research Projects Coor-dination Unit of Istanbul University-Cerrahpasa [35177]
dc.description.sponsorshipThis study was supported by the Scientific Research Projects Coor-dination Unit of Istanbul University-Cerrahpasa (Project number: 35177) . The authors acknowledge to Scientific and Technological Research Application and Research Center, Sinop University, Turkey, for the use of the Bruker D8-QUEST diffractometer.
dc.identifier.doi10.1016/j.cbi.2022.109997
dc.identifier.issn0009-2797
dc.identifier.issn1872-7786
dc.identifier.pmid35654126
dc.identifier.scopus2-s2.0-85131447407
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.cbi.2022.109997
dc.identifier.urihttps://hdl.handle.net/11486/6674
dc.identifier.volume363
dc.identifier.wosWOS:000813296200004
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofChemico-Biological Interactions
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250323
dc.subjectThiosemicarbazone
dc.subjectVanadium complexes
dc.subjectBreast cancer
dc.subjectCytotoxicity
dc.subjectApoptosis
dc.subjectMultidrug resistance
dc.titleNew oxovanadium(IV) complexes overcame drug resistance and increased in vitro cytotoxicity by an apoptotic pathway in breast cancer cells
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu